Dare Bioscience DARE Income Statement (2013-2026)

NASDAQ DARE
$0.72 +0.00 (+0.50%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Dare Bioscience Quarterly Income Statement

Periods 53 quarters
Latest Jun 2026

Dare Bioscience reported revenue of $0.19M and net income of -$2.98M for the quarter ended Jun 2026, up 637.6% year over year. This income statement covers 53 quarters of results from Mar 2013 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Revenue & cost
Revenue
10.00M1.00M1.81M0.01M0.02M0.04M-0.06M0.03M-0.02M0.00M1.02M0.19M
Cost of RevenueCost of Rev
0.01M-0.01M0.30M0.32M
Gross Profit
1.00M0.00M0.02M0.04M-0.06M0.03M-0.02M0.00M0.73M-0.13M
Operating items
Research & DevelopmentR&D
7.34M10.43M7.12M5.81M6.80M4.46M12.98M5.02M6.04M6.67M3.80M3.35M4.93M2.68M3.34M2.30M1.43M1.18M0.62M0.24M
Selling, General & AdministrativeSG&A
1.80M2.21M2.40M2.57M2.79M2.65M3.23M3.34M2.92M2.70M3.15M2.67M2.45M2.04M2.00M2.31M2.38M2.50M1.58M2.59M
Other Operating ExpensesOther Opex
0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.03M0.01M-0.01M
Operating ExpensesOpex
9.16M12.67M9.54M8.40M9.62M7.14M16.23M8.38M8.99M9.40M6.98M6.03M7.38M4.72M5.32M4.61M3.81M3.67M2.20M2.84M
Operating IncomeOp. Inc
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.02M-7.36M-4.68M-5.39M-4.58M-3.83M-3.67M-1.47M-2.97M
EBIT
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.02M-7.36M-4.68M-5.39M-4.58M-3.83M-3.67M-1.47M-2.97M
Non-operating items
Non Operating Interest Expenses
0.21M0.13M
Interest & Investment IncomeInt & Inv Inc
0.09M0.16M
Other Non Operating IncomeOther Non Op Inc.
175.000.00M0.00M0.03M0.12M0.29M0.34M0.23M0.10M0.11M-0.73M-0.11M-0.02M1.84M0.20M-0.19M0.11M-0.28M-0.01M
Non Operating IncomeNon Op. Inc.
Net income details
EBT
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.14M-7.36M-4.68M-5.39M-4.56M-3.83M-3.67M-1.47M-2.97M
Profit After TaxPAT
-9.16M-12.73M-9.53M-8.40M0.41M-7.25M-15.76M-8.04M-8.76M-8.31M-5.00M-6.76M12.91M-4.70M-5.57M-4.38M-4.02M-3.56M-1.40M-2.98M
Income from Continuing OperationsIncome (Continuing)
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.14M-7.36M-4.68M-5.39M-4.56M-3.83M-3.67M-1.47M-2.97M
Consolidated Net IncomeConsol Net Inc.
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.14M-7.36M-4.68M-5.39M-4.56M-3.83M-3.67M-1.47M-2.97M
Income towards Parent CompanyParent Net Inc
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.14M-7.36M-4.68M-5.39M-4.56M-3.83M-3.67M-1.47M-2.97M
Net Income towards Common StockholdersNet Income
-9.16M-12.67M-9.54M-8.40M0.38M-7.02M-15.94M-8.04M-8.99M-8.30M-8.76M-6.14M-7.36M-4.68M-5.39M-4.56M-3.83M-3.67M-1.47M-2.97M
Additional items
EPS (Basic)
-2.18-2.15-1.87-1.200.05-0.99-2.26-1.13-1.25-1.09-1.20-0.73-0.87-0.55-0.63-0.52-0.43-0.29-0.13-0.20
EPS (Diluted)
-2.18-2.15-1.87-1.200.05-0.99-2.26-1.13-1.25-1.09-1.20-0.73-0.87-0.55-0.63-0.52-0.43-0.29-0.13-0.20
Shares Outstanding
4.20M5.90M5.10M7.00M7.06M7.07M7.05M7.13M7.20M7.59M7.28M8.38M8.41M8.53M8.50M8.76M8.87M12.76M11.18M14.89M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
4.20M5.90M5.10M7.00M7.11M7.07M7.05M7.13M7.20M7.59M7.28M8.38M8.48M8.53M8.50M8.76M8.87M12.76M11.18M14.89M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
4.78M6.38M5.10M7.00M7.00M7.00M7.07M7.18M7.22M8.19M8.33M8.38M8.55M8.55M8.70M8.85M9.03M13.93M11.18M15.17M
EBITDA
-9.16M-12.67M-9.54M-8.40M0.38M-7.14M-16.23M-8.38M-8.99M-8.40M-5.17M-6.02M-7.36M-4.68M-5.39M-4.58M-3.83M-3.67M-1.47M-2.97M
Interest ExpensesInt Expense
0.21M0.13M